Figure 1 | Scientific Reports

Figure 1

From: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Figure 1

Inhibition of PP2A by LB100 decreases AML and sAML cell proliferation. (A) LB100 decreased cell proliferation in multiple leukemia cell lines in a dose dependent manner. (B,C) SKM-1 colony formation rate significantly decreased following LB100 treatment in a concentration dependent fashion after 7 days of culture in methylcellulose medium. Images were obtained at x40 magnification. (D) After 6 hours of LB100 treatment, PP2A activity was decreased with increasing concentrations of LB100 in SKM-1 cells. (E) PP2A isoform levels were moderately decreased after receiving 5 μM LB100 treatment for 12 h. Statistically significant differences are marked by an asterisk (*P < 0.05; **P < 0.01, ***P ≤ 0.001).

Back to article page